A retrospective matched study of 16,792 patients with type 2 diabetes found GLP-1 receptor agonist use before necrotizing ...

Please provide your email address to receive an email when new articles are posted on . Among patients with diabetes, those taking a GLP-1 had better 3-year survival rates after PCI for a heart attack ...

New Delhi: Women living with both breast cancer and Type 2 diabetes may have better overall survival if treated with GLP-1 receptor agonists (GLP-1RA) after their cancer diagnosis, according to a new ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. GLP-1 receptor agonists reduced mortality vs. DDP-4 ...

In a new study, colon cancer patients on these medications were more likely to make it to the 5-year survival mark than patients not on the drugs. In a new study, colon cancer patients who took GLP-1 ...

Patients with colon cancer using GLP-1 receptor agonists (the class of drugs behind treatments like Ozempic, Wegovy, and Mounjaro) had substantially lower five-year death rates than those not using ...

Lower optic neuritis incidence also observed ...

In a retrospective analysis, patients with colon cancer taking GLP-1 agonists had a 62% lower risk of 5-year mortality compared with those not taking the drugs. The mortality benefit was statistically ...

Cuomo notes that while these results are observational, they underscore an urgent need for clinical trials to test whether GLP-1 drugs can improve cancer survival rates, especially for patients with ...

Breast cancer is one of the most common cancers in the United States, accounting for 30% of all new female cancers each year. Individuals with breast cancer that co-occurs with obesity or type 2 ...

Colon cancer patients could live longer if they take GLP-1 drugs like Ozempic and Wegovy, a new study suggests. Researchers at UC San Diego studied more than 6,800 patients who were taking one of ...

GLP-1 receptor agonists affect metabolic, inflammatory, and neuronal survival pathways implicated in Parkinson’s disease, ...